Medicines Discovery Catapult invests in UK biotech pioneers developing novel treatments for chronic diseases
Investment and expert support will help accelerate the development of new treatments for a range of autoimmune, inflammatory, and age-related diseases
Two UK biotechs developing novel approaches to treating diseases such as psoriasis and Parkinson’s have secured investment and strategic support from Medicines Discovery Catapult (MDC) to accelerate their progress.
Flip Therapeutics and Nascent Therapeutics will each receive £500,000 in funding made available by Innovate UK as part of a scheme that enabled Catapults to invest in high-potential companies.